Abbott Laboratories (ABT) Expected to Announce Earnings on Thursday

Abbott Laboratories (NYSE:ABT) is expected to be issuing its Q4 2025 results before the market opens on Thursday, January 22nd. Analysts expect the company to announce earnings of $1.50 per share and revenue of $11.8006 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, January 22, 2026 at 9:00 AM ET.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. The business had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.21 EPS. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Stock Performance

ABT opened at $124.90 on Thursday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $126.12 and its 200-day moving average is $129.14. The stock has a market cap of $217.18 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 2.06 and a beta of 0.72. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. Abbott Laboratories’s payout ratio is presently 29.57%.

Institutional Trading of Abbott Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the company. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares during the last quarter. United Bank lifted its holdings in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the period. Nikulski Financial Inc. lifted its stake in shares of Abbott Laboratories by 1.1% in the 2nd quarter. Nikulski Financial Inc. now owns 9,952 shares of the healthcare product maker’s stock valued at $1,354,000 after purchasing an additional 109 shares during the period. Finally, First Foundation Advisors boosted its position in shares of Abbott Laboratories by 5.6% in the 3rd quarter. First Foundation Advisors now owns 9,956 shares of the healthcare product maker’s stock worth $1,334,000 after purchasing an additional 527 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABT. Mizuho lifted their target price on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Jefferies Financial Group boosted their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Raymond James Financial lifted their target price on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Finally, Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $147.68.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.